Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.

Authors :: Luke, Jason J.
Ascierto, Paolo Antonio
Khattak, Muhammad Adnan
de la Cruz Merino, Luis
Del Vecchio, Michele
Rutkowski, Piotr
Spagnolo, Francesco
Mackiewicz, Jacek
Chiarion-Sileni, Vanna
Kirkwood, John M. M.
Robert, Caroline
Grob, Jean-Jacques
de Galitiis, Federica
Schadendorf, Dirk
Carlino, Matteo S.
Wu, Larry
Fukunaga-Kalabis, Mizuho
Krepler, Clemens
Eggermont, Alexander M.
Long, Georgina V.
Source :: Journal of Clinical Oncology; 6/10/2023 Supplement17, Vol. 41, pLBA9505-LBA9505, 1p
Publication Year :: 2023

Full Text Access

Tools